参考文献/References:
[1]Mikolasevic I,Milic S,Turk Wensveen T,et al.Nonalcoholic fatty liver disease - A multisystem disease?[J].World J Gastroenterol,2016,22(43):9488-9505.[2]VanWagner LB,Rinella ME.Extra-hepatic manifestations of nonalcoholic fatty liver disease[J].Curr Hepatol Rep,2016,15(2):75-85.[3]高鑫.非酒精性脂肪性肝病更名带来的新思考[J].临床肝胆病杂志,2020,36(6):1201-1204.[4]Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asian[J].J Hepatol,2017,67(4):862-873.[5]Younossi Z,Tacke F,Arrese M,et al.Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].Hepatology,2019,69(6):2672-2682.[6]Zou ZY,Fan JG.Incidence of chronic kidney disease inpatients with nonalcoholic fatty liver disease[J].J Hepatol,2020,73(1):214-216. [7]Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction associated fatty liver disease:An international expert consensus statement[J].J Hepatol,2020,73(1):202-209.[8]Al Rifai M,Silverman MG,Nasir K,et al.The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)[J].Atherosclerosis,2015,239(2):629-633.[9]Non-alcoholic Fatty Liver Disease Study Group,Lonardo A,Bellentani S,et al.Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups[J].Dig Liver Dis,2015,47(12):997-1006.[10]Yan LH,Mu B,Guan Y,et al.Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications[J].J Diabetes Investig,2016,7(6):889-894.[11]Kim TK,Won JY,Shin JA,et al.The association of metabolic syndrome with diabetic retinopathy: The Korean national health and nutrition examination survey 2008-2012[J].PLoS One,2016,11(6):e0157006.[12]Gao L,Xin Z,Yuan MX,et al.High prevalence of diabetic retinopathy in diabetic patients concomitant with metabolic syndrome[J].PLoS One,2016,11(1):e0145293.[13]Vollenweider P,von Eckardstein A,Widmann C.HDLs,diabetes,and metabolic syndrome[J].Handb Exp Pharmacol,2015(224):405-421.[14]Katsiki N,Mikhailidis DP,Mantzoros CS.Non-alcoholic fatty liver disease and dyslipidemia: An update[J].Metabolism,2016,65(8):1109-1123.[15]Nam JS,Jo S,Kang S,et al.Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults[J].Clin Chim Acta,2016(461):14-18.[16]Zidi W,AllalElasmi M,Zayani Y,et al.Metabolic syndrome,independent predictor for coronary artery disease[J].Clin Lab,2015,61(10):1545-1552.[17]Vassallo P,Driver SL,Stone NJ.Metabolic syndrome: An evolving clinical construct[J].Prog Cardiovasc Dis,2016,59(2):172-177.[18]Tie HT,Shi R,Li ZH,et al.Risk of major adverse cardiovascular events in patients with metabolic syndrome after revascularization: A meta-analysis of eighteen cohorts with 18,457 patients[J].Metabolism,2015,64(10):1224-1234.[19]Mantovani A,Ballestri S,Lonardo A,et al.Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease[J].Dig Dis Sci,2016,61(5):1246-1267.[20]Francque SM,van der Graaff D.Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications[J].J Hepatol,2016,65(2):425-443.[21]Wong VW,Wong GL,Yeung JC,et al.Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study[J].Hepatology,2016,63(3):754-763.[22]Katsiki N,Athyros VG,Karagiannis A,et al.Should we expand the concept of coronary heart disease equivalents?[J].Curr Opin Cardiol,2014,29(4):389-395.[23]Katsiki N,Athyros VG,Mikhailidis DP.Abnormal peri-organ or intra-organ fat (APIFat) deposition: An underestimated predictor of vascular risk?[J].Curr Vasc Pharmacol,2016,14(5):432-441.[24]Uygun A,Kadayifci A,Demirci H,et al.The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis[J].Eur J Intern Med,2015(26):37-41.[25]Tariq H,Nayudu S,Akella S,et al.Non-alcoholic fatty pancreatic disease: A review of literature[J].Gastroenterology Res,2016,9(6):87-91.[26]Alempijevic T,Dragasevic S,Zec S,et al.Non-alcoholic fatty pancreas disease[J].Postgrad Med J,2017,93(1098):226-230.[27]Haberka M,Gasior Z.Carotid extra-media thickness in obesity and metabolic syndrome: A novel index of perivascular adipose tissue:Extra-media thickness in obesity and metabolic syndrome[J].Atherosclerosis,2015,239(1):169-177.[28]Prasad GV.Metabolic syndrome and chronic kidney disease: Current status and future directions[J].World J Nephrol,2014,3(4):210-219.[29]Musso G,Cassader M,Cohney S,et al.Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities[J].Diabetes Care,2016,39(10):1830-1845.[30]Kirpich IA,Marsano LS,McClain CJ.Gut-liver axis,nutrition,and non-alcoholic fatty liver disease[J].Clin Biochem,2015,48(13-14):923-930.[31]Quigley EM,Abu-Shanab A,Murphy EF,et al.The metabolic role of the microbiome: Implications for NAFLD and the metabolic syndrome[J].Semin Liver Dis,2016,36(4):312-316.[32]Bashiardes S,Shapiro H,Rozin S,et al.Non-alcoholic fatty liver and the gut microbiota[J].Mol Metab,2016,5(9):782-794.[33]Mortada R,Williams T.Metabolic syndrome: Polycystic ovary syndrome[J].FP Essent,2015(435):30-42.[34]Wimalawansa SJ.Associations of vitamin D with insulin resistance,obesity,type 2 diabetes,and metabolic syndrome[J].J Steroid Biochem Mol Biol,2018(175):177-189.[35]Kaya E,Sikka SC,Gur S.A comprehensive review of metabolic syndrome affecting erectile dysfunction[J].J Sex Med,2015,12(4):856-875.[36]Duman DG,Bicakci E,Celikel CA,et al.Nonalcoholic fatty liver disease is associated with erectile dysfunction: A prospective pilot study[J].J Sex Med,2016,13(3):383-388.[37]Aron-Wisnewsky J,Clement K,Pépin JL.Nonalcoholic fatty liver disease and obstructive sleep apnea[J].Metabolism,2016,65(8):1124-1135.[38]Garcia M,Bihuniak JD,Shook J,et al.The effect of the traditional mediterranean-style dieton metabolic risk factors: A meta-analysis[J].Nutrients,2016,8(3):168.[39]Sofi F,Casini A.Mediterranean diet and non-alcoholic fatty liver disease: New therapeutic option around the corner?[J].World J Gastroenterol,2014,20(23):7339-7346.[40]Ladeiras-Lopes R,Fontes-Carvalho R,Bettencourt N,et al.Novel therapeutic targets of metformin:Metabolic syndrome and cardiovascular disease[J].Expert Opin Ther Targets,2015,19(7):869-877.[41]Macauley M,Hollingsworth KG,Smith FE,et al.Effect of vildagliptin on hepatic steatosis[J].J Clin Endocrinol Metab,2015,100(4):1578-1585.[42]Athyros VG,Katsiki N,Mikhailidis DP.Editorial: Resolution of non-alcoholic-steatohepatitis.more than one drug needed?[J].Curr Vasc Pharmacol,2016,14(4):313-315.[43]Srikanth S,Deedwania P.Management of dyslipidemia in patients with hypertension,diabetes,and metabolic syndrome[J].Curr Hypertens Rep,2016,18(10):76.[44]Kushner PA,Cobble ME.Hypertriglyceridemia: The importance of identifying patients at risk[J].Postgrad Med,2016,128(8):848-858.[45]Athyros VG,Alexandrides TK,Bilianou H,et al.The use of statins alone,or in combination with pioglitazone and other drugs,for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk.An Expert Panel Statement[J].Metabolism,2017(71):17-32.[46]Simon TG,Corey KE,Chung RT,et al.Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease: The potential role of ezetimibe[J].Dig Dis Sci,2016,61(12):3425-3435.[47]Alam S,Kabir J,Mustafa G,et al.Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial[J].Saudi J Gastroenterol,2016,22(1):69-76.[48]Omran Z.Obesity: Current treatment and future horizons[J].Mini Rev Med Chem,2017,17(1):51-61.[49]Bower G,Toma T,Harling L,et al.Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology[J].Obes Surg,2015,25(12):2280-2289.[50]Aguilar-Olivos NE,Almeda-Valdes P,Aguilar-Salinas CA,et al.The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome[J].Metabolism,2016,65(8):1196-1207.[51]Corcelles R,Daigle CR,Schauer PR.Management of endocrine disease: Metabolic effects of bariatric surgery[J].Eur J Endocrinol,2016,174(1):19-28.
相似文献/References:
[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(01):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]崔姗姗,刘 英,江 霞.非酒精性脂肪性肝病与胰岛素抵抗的研究进展[J].医学信息,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
CUI Shan-shan,LIU Ying,JIANG Xia.Research Progress on Non-alcoholic Fatty Liver Disease and Insulin Resistance[J].Medical Information,2022,35(01):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
[3]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Medical Information,2018,31(01):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[4]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Medical Information,2018,31(01):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[5]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of
Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(01):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[6]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in
A Certain Area of Tianjin[J].Medical Information,2019,32(01):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[7]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2019,32(01):38.[doi:10.3969/j.issn.1006-1959.2019.14.014]
[8]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病
中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with
Nonalcoholic Fatty Liver Disease[J].Medical Information,2019,32(01):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
[9]蒋晓倩,梁惠卿,刘垚昱,等.吴耀南运用“浊毒”理论论治非酒精性脂肪性肝病验案举隅[J].医学信息,2020,33(04):158.[doi:10.3969/j.issn.1006-1959.2020.04.052]
[10]蔡秀媛,吴春城,梁惠卿,等.非酒精性脂肪性肝病中医证型与客观指标的相关性[J].医学信息,2020,33(09):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]
CAI Xiu-yuan,WU Chun-cheng,LIANG Hui-qing,et al.Correlation Between TCM Syndromes of Nonalcoholic Fatty Liver Disease and Objective Indexes[J].Medical Information,2020,33(01):21.[doi:10.3969/j.issn.1006-1959.2020.09.008]